HA35
PreclinicalSmall molecule
HA35 is one of 12 small molecule programs targeting Myofascial Pain Syndrome. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Myofascial Pain Syndrome
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Xylocaine
CCitius Pharmaceuticals, Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 2
Botox
RRevance Therapeutics, Inc.
Preclinical
Marcaine
IInnocoll
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HA35. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNakhia Impex LLC